Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease

BackgroundAlzheimer's disease (AD) accompanied by psychotic symptoms (PS) has a poor prognosis and may be associated with imbalances in key neural proteins such as alpha-synuclein (AS). AimThe aim of the study was to evaluate the diagnostic validity of AS levels in the cerebrospinal fluid (CSF)...

Full description

Bibliographic Details
Authors: Monge-García S, García-Ayllón MS, Sánchez-Payá J, Gasparini-Berenguer R, Cortés-Gómez MÁ, Sáez-Valero J, Monge-Argilés JA
Format: article
Status:Published version
Publication Date:2023
Country:España
Institution:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repository:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p15326
Online Access:https://fisabio.portalinvestigacion.com/publicaciones/15326
Access Level:Open access
Keyword:psychosis
Alzheimer
alpha-synuclein
CSF
biomarkers
id ES_aaa88027cb20823df7f3c97c2d343e8d
oai_identifier_str oai:fisabio.fundanetsuite.com:p15326
network_acronym_str ES
network_name_str España
repository_id_str
spelling Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's diseaseMonge-García SGarcía-Ayllón MSSánchez-Payá JGasparini-Berenguer RCortés-Gómez MÁSáez-Valero JMonge-Argilés JApsychosisAlzheimeralpha-synucleinCSFbiomarkersBackgroundAlzheimer's disease (AD) accompanied by psychotic symptoms (PS) has a poor prognosis and may be associated with imbalances in key neural proteins such as alpha-synuclein (AS). AimThe aim of the study was to evaluate the diagnostic validity of AS levels in the cerebrospinal fluid (CSF) as a predictor of the emergence of PS in patients with prodromal AD. Materials and methodsPatients with mild cognitive impairment were recruited between 2010 and 2018. Core AD biomarkers and AS levels were measured in CSF obtained during the prodromal phase of the illness. All patients who met the NIA-AA 2018 criteria for AD biomarkers received treatment with anticholinesterasic drugs. Follow-up evaluations were conducted to assess patients for the presence of psychosis using current criteria; the use of neuroleptic drugs was required for inclusion in the psychosis group. Several comparisons were made, taking into account the timing of the emergence of PS. ResultsA total of 130 patients with prodromal AD were included in this study. Of these, 50 (38.4%) met the criteria for PS within an 8-year follow-up period. AS was found to be a valuable CSF biomarker to differentiate between the psychotic and non-psychotic groups in every comparison made, depending on the onset of PS. Using an AS level of 1,257 pg/mL as the cutoff, this predictor achieved at least 80% sensitivity. ConclusionTo our knowledge, this study represents the first time that a CSF biomarker has shown diagnostic validity for prediction of the emergence of PS in patients with prodromal AD.FRONTIERS MEDIA SA2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/15326Frontiers in NeurologyISSN: 16642295reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p153262026-06-11T12:45:17Z
dc.title.none.fl_str_mv Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease
title Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease
spellingShingle Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease
Monge-García S
psychosis
Alzheimer
alpha-synuclein
CSF
biomarkers
title_short Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease
title_full Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease
title_fullStr Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease
title_full_unstemmed Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease
title_sort Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease
dc.creator.none.fl_str_mv Monge-García S
García-Ayllón MS
Sánchez-Payá J
Gasparini-Berenguer R
Cortés-Gómez MÁ
Sáez-Valero J
Monge-Argilés JA
author Monge-García S
author_facet Monge-García S
García-Ayllón MS
Sánchez-Payá J
Gasparini-Berenguer R
Cortés-Gómez MÁ
Sáez-Valero J
Monge-Argilés JA
author_role author
author2 García-Ayllón MS
Sánchez-Payá J
Gasparini-Berenguer R
Cortés-Gómez MÁ
Sáez-Valero J
Monge-Argilés JA
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv psychosis
Alzheimer
alpha-synuclein
CSF
biomarkers
topic psychosis
Alzheimer
alpha-synuclein
CSF
biomarkers
description BackgroundAlzheimer's disease (AD) accompanied by psychotic symptoms (PS) has a poor prognosis and may be associated with imbalances in key neural proteins such as alpha-synuclein (AS). AimThe aim of the study was to evaluate the diagnostic validity of AS levels in the cerebrospinal fluid (CSF) as a predictor of the emergence of PS in patients with prodromal AD. Materials and methodsPatients with mild cognitive impairment were recruited between 2010 and 2018. Core AD biomarkers and AS levels were measured in CSF obtained during the prodromal phase of the illness. All patients who met the NIA-AA 2018 criteria for AD biomarkers received treatment with anticholinesterasic drugs. Follow-up evaluations were conducted to assess patients for the presence of psychosis using current criteria; the use of neuroleptic drugs was required for inclusion in the psychosis group. Several comparisons were made, taking into account the timing of the emergence of PS. ResultsA total of 130 patients with prodromal AD were included in this study. Of these, 50 (38.4%) met the criteria for PS within an 8-year follow-up period. AS was found to be a valuable CSF biomarker to differentiate between the psychotic and non-psychotic groups in every comparison made, depending on the onset of PS. Using an AS level of 1,257 pg/mL as the cutoff, this predictor achieved at least 80% sensitivity. ConclusionTo our knowledge, this study represents the first time that a CSF biomarker has shown diagnostic validity for prediction of the emergence of PS in patients with prodromal AD.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/15326
url https://fisabio.portalinvestigacion.com/publicaciones/15326
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv FRONTIERS MEDIA SA
publisher.none.fl_str_mv FRONTIERS MEDIA SA
dc.source.none.fl_str_mv Frontiers in Neurology
ISSN: 16642295
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869416200675524608
score 15,812429

Similar Items